May 17, 2024 7:12am
I am more frequently right than consequentially wrong; if you want to be liked, don’t be an analyst/journalist.
Pre-Open Indications: 1 Sell into Strength, 1 Positive and 1 Negative Indications
A daily analytic discipline is constructed by period updates and specific warnings of emerging situations
Never leave an investor uninformed
Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.
Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RMi
Friday: The pre-open Dow futures are DOWN -0.03% or (-12 points), the S&P futures are DOWN -0.04% or (-2 points), as the Nasdaq futures are UP +0.05% or (+10 points)
Futures traded mixed and flat on Friday,
European markets lower,
Asia Pacific markets were also mixed mostly declining
Henry’omics:
We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …
Thursday: The Dow closed DOWN -38.62 points or -0.10%, the S&P closed DOWN -11.05 points or -0.21% while the Nasdaq closed DOWN -44.07 points or -0.26%
- Thursday’s advance/decline line at the open was negative with 9 incliner, 25 decliners and 1 flat; ending with a negative close of 13 incliners, 21 decliners and 1 flat
Despite the weak end to Thursday’s session, the indexes are on track to end the week with gains. The Nasdaq is leading the way with a 2.2% advance, followed by the S&P 500′s 1.4% rise and the Dow is tracking to close the week 0.9% higher.
This week’s ascent has helped propel the three indexes into positive territory for Q2 despite a tough start; the S&P 500 and Nasdaq are now each up more than 11% in 2024, while the Dow has climbed more than 5% on the year.
Economic Data Docket: Leading index, April (-0.3% expected, -0.3% previously)
Thursday’s night’s RegMed Investors (RMi) Closing Bell: “There is STILL many a concern of sentiment and conviction in the cell and gene therapy sector. Remember the myth of Icarus flying too high and melting his wings with a big drop to the sea.” … https://www.regmedinvestors.com/articles/13464
Q2/24: May – 8 positive and 4 negative closes
- April - 16 negative and 6 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context:
I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Sell into Strength Indication:
Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Ultragenyx Pharmaceuticals (RARE) closed up +$1.49 with a positive +$0.22 or +0.52% pre-open indication.
Negative Indications:
Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Blueprint Medicine (BPMC) closed down -$0.15 after Wednesday’s +$1.33, Tuesday’s -$2.59, Monday’s +$1.35 and last Friday’s -$1.64 with a neutral pre-open indication.
Positive Indication:
Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Intellia Therapeutics (NTLA) closed down -$0.05 after Wednesday’s +$0.49, Tuesday’s +$0.31, Monday’s +$0.96 and last Friday’s -$0.40 with a positive +$0.13 or +0.50% pre-open indication
The BOTTOM LINE: The cell and gene therapy sector took a hit Thursday after 3 positive sessions. Last week, there were 2 positive and 3 negative sessions.
While the stock market rally rose Thursday morning, fading for slim losses, but it was a relatively tame session.
- One can take a good or bad feeling, re-frame it, and suddenly that feeling is the solution.
- Not me, I don’t run from any feeling but, take that sensation itself as a sharpened stick to “poke’ mainstream thinking.
“I’ve been a few miles, and I’ve seen a few things. What I’m trying to do is just say, look, I don’t know everything, but I know some things—let me level with you. Based on my experience … this is what’s happening.”
- I suggest that it is better to keep your finger on the sell button but, still keep a buy ticket in the other hand!
- So, trade some ups, don’t be so fast in buying into few bottoms, build cash position.
RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
